OS Therapies Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by OS Therapies Inc. (OSTX) on July 23, 2026, regarding events occurring on that date. The Company is an emerging growth company incorporated in Delaware with principal executive offices in Grasonville, Maryland.
Key Financial Metrics
The filing does not report standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed relates to a specific equity issuance program:
- Total Offering Capacity: $18,000,000 under the At Market Issuance Sales Agreement.
- Shares Sold: 282,679 shares of common stock.
- Gross Proceeds Received: Approximately $530,162.
- Remaining Capacity: Approximately $17,469,838.
Material Changes
The primary material change reported is the termination of the At Market Issuance Sales Agreement dated August 8, 2025, with B. Riley Securities, Inc. and JonesTrading Institutional Services LLC. The Company delivered written notice of termination on July 23, 2026, with the termination becoming effective on July 28, 2026. Consequently, no further shares may be offered or sold under this agreement.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or discussion of general business risks. The termination of the Sales Agreement was executed without any termination fees or other payments due by either party. The Company has not provided a clear value for future capital raising plans in this document.
Key Facts for Investor Verification
- Verify the Company's current cash position and runway, given the termination of the $18 million equity sales facility with only ~$0.53 million raised.
- Confirm if the Company has initiated alternative financing strategies to replace the terminated Sales Agreement.
- Review recent trading volume and price of OSTX common stock to assess market reaction to the termination.
- Check for any subsequent filings regarding new material definitive agreements or capital raises.